News

NeuroCog Trials, Inc. announces support for the cognitive outcomes of a new global Phase 3 clinical trial. This study investigates a genetic-based biomarker risk assignment algorithm to predict risk of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) within a five year period.

NeuroCog Trials, Inc. announces that they have begun providing support for the cognitive outcomes of a new global Phase 3 clinical trial. This study investigates a genetic-based biomarker Trial Press Release: NeuroCog Trials, Inc. announces support for the cognitive...

read more